Ian Haydock
Editor-in-Chief, Asia-Pacific at Scrip
Editor-in-Chief, Asia-Pacific at The Pink Sheet
Tokyo-based Editor-in-Chief, Asia-Pacific, for @PharmaScrip @PharmaPinkSheet, @citeline, @NorstellaCo. All views my own, RTs not endorsements.
Articles
-
1 week ago |
insights.citeline.com | Ian Haydock
Shionogi In $1bn Deal For Japan Tobacco’s Pharma OpsMid-Tier Consolidation With ToriiMid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business in Japan, in bid to build sales reach and manufacturing. Japanese mid-sized pharma firms to merge (Shutterstock)
-
1 week ago |
insights.citeline.com | Ian Haydock
Quick Listen: Scrip’s Five Must-Know ThingsIn this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data. weekly audio roundup of selected content from Scrip's global team
-
2 weeks ago |
insights.citeline.com | Ian Haydock
Quick Listen: Scrip’s Five Must-Know Things In this week's episode: 2024’s top-selling drugs; two CEOs call for higher Europe drug prices; diabetes trial win for Lilly’s orforglipron; BMS trial failure in schizophrenia; and an analysis of alliance deal-making last year. weekly audio roundup of selected content from Scrip's global team
-
3 weeks ago |
insights.citeline.com | Ian Haydock
Quick Listen: Scrip’s Five Must-Know Things In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain. weekly audio roundup of selected content from Scrip's global team
-
1 month ago |
insights.citeline.com | Ian Haydock
Quick Listen: Scrip’s Five Must-Know Things In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation. weekly audio roundup of selected content from Scrip's global team
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 982
- Tweets
- 9K
- DMs Open
- No
RT @PharmaScrip: BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne https://t.co/souAMXk0aM #PharmaScrip https://t.co/C2wvraG…
Nice original story by Xu Hu for @PharmaScrip on a globally hot area for #pharma
Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles https://t.co/3dxnJT7d2y #PharmaScrip https://t.co/Xx8tQ0uHAM
Great interview by Dexter Yan for @PharmaScrip on how Zai is pivoting to innovation #pharma Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets https://t.co/I6wlX4csG5